Stabilized interferon liquid formulations
First Claim
1. A stabilized liquid pharmaceutical composition comprising an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant.
1 Assignment
0 Petitions
Accused Products
Abstract
Stabilized liquid pharmaceutical composition comprising an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said formulation is a solution that comprises a buffer, a cyclodextrin, an isotonicity agent and an anti-oxidant are described here. Preferably the interferon is interferon beta-1a and the cyclodextrin is HPBCD. These formulations are stable at room temperature, thus bringing the advantage of lower costs for formulation storage and increased safety for the patient with respect to possible “errors” during handling. As a matter of fact, having such formulations stable at room temperature reduces the risk of formation of degradation products potentially responsible for adverse events (e.g. immunogenicity).
-
Citations
37 Claims
- 1. A stabilized liquid pharmaceutical composition comprising an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant.
-
25. A method for preparing a stabilized liquid pharmaceutical composition comprising adding calculated amounts of 2-hydroxypropyl-beta-cyclodextrin, antioxidant and isotonicity agent to the buffered solution and then adding interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof.
-
26-31. -31. (canceled)
-
32. An article of manufacture comprising a container containing a stabilized liquid pharmaceutical composition comprising:
-
a) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant;
b) interferon-beta (IFN-beta) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant;
c) recombinant interferon-beta (IFN-beta) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant;
d) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent, an anti-oxidant and a buffer that is present in an amount sufficient to maintain the pH of said composition within plus or minus 0.5 units of a specified pH, wherein the specified pH is about 3 to about 6;
e) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent, an anti-oxidant and a buffer that is present in an amount sufficient to maintain the pH of said composition within plus or minus 0.5 units of a specified pH, wherein said pH is 3.8;
f) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein said buffer is present at a concentration of about 5 mM to 500 mM;
g) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein said buffer is present at a concentration of about 50 mM;
h) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises an acetate buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant;
i) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein said isotonicity agent is mannitol;
j) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein said isotonicity agent is present at a concentration of about 0.5 mg/ml to about 500 mg/ml;
k) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein said isotonicity agent is present at a concentration of about 50 mg/ml;
l) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein said the antioxidant is methionine;
m) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein said the antioxidant is present at a concentration of about 0.01 to about 5 mg/ml;
n) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein said the antioxidant is present at a concentration of about about 0.1 mg/ml;
o) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein said interferon is present at a concentration of about 10 μ
g/ml to about 800 μ
g/ml;
p) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein said cyclodextrin is present at a molar ratio vs. interferon of from 500-fold molar excess up to 700-fold molar excess;
q) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein said interferon is present at a concentration of about 44, 88 or 276 μ
g/ml;
r) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein said composition is an aqueous solution;
s) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent, an anti-oxidant and a bacteriostatic agent;
t) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent, an anti-oxidant and a bacteriostatic agent, wherein said bacteriostatic agent is benzyl alcohol;
u) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent, an anti-oxidant and a bacteriostatic agent, wherein said bacteriostatic agent is present at a concentration of about 0. 1% to about 2%;
v) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent, an anti-oxidant and a bacteriostatic agent, wherein said bacteriostatic agent is present at a concentration of about 0.2 or 0.3%;
w) an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein the isotonicity agent is mannitol, the anti-oxidant is methionine and the interferon is interferon beta;
orx) a composition comprising an interferon (IFN) or an isoform, mutein, fused protein, functional derivative, active fraction or salt thereof, wherein said composition is a solution that comprises a buffer, 2-hydroxypropyl-beta-cyclodextrin, an isotonicity agent and an anti-oxidant, wherein the composition is the following liquid formulation;
Interferon beta-1a 44 μ
g/mLHPBCD 1.9 mg/mL Methionine 0.1 mg/mL Mannitol 50 mg/mL acetate buffer up to 1 mL ; and
wherein said container is hermetically sealed in conditions that are sterile and appropriate for storage prior to use. - View Dependent Claims (33, 34, 35, 36, 37)
-
Specification